Navigation Links
AcelRx Pharmaceuticals Receives First U.S. Patent for Small-Volume Oral Transmucosal Dosage Forms
Date:6/20/2012

-looking statements, including, but not limited to, statements related to AcelRx Pharmaceuticals' patent portfolio, including the useful life of the U.S. patent for a method of treating pain by administering a small-volume solid tablet containing sufentanil by adhering to the oral mucosa, the continued expansion of its patent protection, market exclusivity, its ability to protect its proprietary technology, the scope of patent protection, and issued and planned or anticipated future clinical development of AcelRx Pharmaceuticals' product candidates, including the initiation of the third Phase 3 clinical studies for ARX-01, the timing of the top-line data from all three clinical trials, the timing of submission of an NDA with the FDA, and the therapeutic potential of AcelRx Pharmaceuticals' product candidates.  These forward-looking statements are based on AcelRx Pharmaceuticals' current expectations and inherently involve significant risks and uncertainties.    AcelRx Pharmaceuticals' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to: the success, cost and timing of AcelRx Pharmaceuticals' product development activities and clinical trials; the success of its patent prosecution strategy; its ability to protect its proprietary technology, including the risks that pending patent applications may not result in issued patents; its ability to obtain sufficient financing to complete development and registration of its product candidates in the United States and Europe; its ability to obtain and maintain regulatory approvals of its product candidates; the market potential for its product candidates; and other risks detailed in the "Risk Factors" and elsewhere in AcelRx Pharmaceuticals' U.S. Securities and Exchange Commission filings, including its Annual Report on Form 10-K for the Year
'/>"/>
SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology news :

1. Fish show autism-like gene expression in water with psychoactive pharmaceuticals
2. Tokai Pharmaceuticals galeterone well-tolerated in patients with advanced prostate cancer
3. From scourge to saint: E. coli bacteria becomes a factory - to make cheaper, faster pharmaceuticals
4. UCLAs Yi Tang receives Presidential Green Chemistry Challenge Award from EPA
5. Leading statistician receives national citation award
6. Dr. Karen Lloyd receives WHOIs Holger W. Jannasch Visiting Scholar Award
7. SF State biology department receives $1.5 million to support science teaching
8. SRI Sarnoffs Iris on the MoveĀ® N-Glanceā„¢ Identification System Receives Lenel Factory Certification
9. Washington University receives $8 million to lead international childhood malnutrition effort
10. UC Riverside receives grant for global health and development research
11. UC Riverside plant cell biologist receives top scientific honor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... and POINT ROBERTS, Washington , ... Play a Key Role in Addressing Security Concerns in the ... a global news source covering leading sectors including biometrics, issues ... market. Jason Peaslee , Managing Partner at ... and Gino Pereira , CEO of NXT-ID, Inc. (OTCBB: ...
(Date:8/19/2014)... used in supermarkets to encourage healthier spending habits? A ... that very question by tracking the purchasing records in ... to rate the nutritional value of foods for sale. ... David Just, PhD, and Brian Wansink PhD, author of ... over 150 Hannaford Supermarkets in the Northeastern United States ...
(Date:8/19/2014)... In many parts of the world, leprosy and ... new cases of leprosy per year, with nearly ... The currently available century-old vaccine Bacille Calmette-Guerin, or ... and leprosy, so a more potent vaccine is ... have found a stronger weapon against both diseases., ...
Breaking Biology News(10 mins):Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 2Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 3Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 4Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 5Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 6Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 7New vaccine shows promise as stronger weapon against both tuberculosis and leprosy 2
... French . , Quebec City, August 25, 2011A diet rich ... according to a study conducted by Universit Laval researchers. The team, ... extent of brain damage following a stroke was reduced by 25% ... study can be found on the website of the journal ...
... DURHAM, N.C. Aerobic exercise is your best bet when ... study finds. When Duke University Medical Center researchers conducted ... combination of the two, they found aerobic exercise to be ... belly fat that,s most damaging to your health. This ...
... have developed the first practical method to create a compound ... naturally in a species of moss found in China, is ... disease in China since the late 1990s and is sold ... memory. Scientists believe it could also potentially combat the effects ...
Cached Biology News:Omega-3s reduce stroke severity 2Aerobic exercise bests resistance training at burning belly fat 2Scientists create natural Alzheimer's-fighting compound in lab 2
(Date:8/20/2014)... university inventions licensed to biotechnology firms has revealed ... open these roadblocks, the researchers suggest that better ... stage could lead to faster commercialization down the ... discoveries made in university laboratories and licensed to ... trials, which have a high failure rate. But ...
(Date:8/20/2014)... Aug. 20, 2014 Neurotrope, Inc. (OTCQB: ... conference call to provide an update on Company ... daylight timeDial-in numbers:(888) 505-4369 (U.S. and Canada) or ... cast: www.neurotropebioscience.com , under "Investor Relations"The teleconference replay ... through September 2, 2014 at (888) 203-1112 (U.S. ...
(Date:8/20/2014)... Aug. 20, 2014  PAREXEL International Corporation (NASDAQ: ... presenting at the Baird Healthcare Conference in New York.  ... Financial Officer, will be making a presentation on PAREXEL ... Wednesday, Sept. 3, 2014. A live webcast ... section of PAREXEL,s website at www.PAREXEL.com in ...
(Date:8/20/2014)... , Aug. 20, 2014 /PRNewswire-iReach/ -- A ... transformative collaboration between the school,s bioengineering department and ... of the Intel® Software Academic Program, UCSD,s research ... and the human body.  Photo ... study exhibits the work of Dr. Todd ...
Breaking Biology Technology:Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3Neurotrope To Host Conference Call 2PAREXEL International To Present At Baird Healthcare Conference 2Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2
... Crystal Research Associates, LLC announced today that it ... Inc. (NYSE Amex: CUR ). The full ... .Neuralstem, Inc. ("Neuralstem" or "the Company") is a ... stem cells to treat central nervous system (CNS) diseases. ...
... /PRNewswire-Asia/ -- Pharmaxis Ltd (AXS: PXS;,Nasdaq: PXSL ) ... afternoon of Wednesday 8th April 2009. Dr Alan Robertson ... quarter and answer,investor questions. , The ... 8th April at 6.00pm U.S. East Coast, 3.00pm U.S. West ...
... April 6 Cell Therapeutics, Inc. (CTI) (Nasdaq and ... from Spectrum Pharmaceuticals, Inc. (Spectrum) in connection with the ... venture to Spectrum for approximately $16.5 million that closed ... on March 2, 2009, related to this transaction, and ...
Cached Biology Technology:Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Neuralstem, Inc. 2Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Neuralstem, Inc. 3CTI Receives the Second Payment of $6.5 million Associated with the Sale of Interest in Zevalin Joint Venture 2CTI Receives the Second Payment of $6.5 million Associated with the Sale of Interest in Zevalin Joint Venture 3
... isolated fromStreptomyces griseolusthat inhibits protein synthesis. ... in eukaryote ribosomes. Reported to induce ... including promyelocytic leukemia cells, Jurkat cells, ... Initiates intracellular signals and immediate early ...
... RC DC protein assay kit I provides reagents ... in the presence of reducing agents and detergents. ... assay. The kit includes reagents and standards sufficient ... I, 250 ml RC reagent II, 250 ml ...
Recommended for use as a cell culture substratum at 0.1-0.2 mg/cm 2 or 5-10 μl/cm 2 . Optimal concentration depends on cell type as well as the application or research objectives. Type B...
... state-of-the-art separation system using the asymmetric flow ... integrates easily with Wyatts multi-angle light scattering ... as the Optilab DSP. The combined system ... of the particles/molecules separated by the AFFF ...
Biology Products: